208 results on '"Rocci, Alberto"'
Search Results
2. Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma
3. Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial
4. Retraction Notice to: Downregulation of p53-inducible microRNAs 192, 194, and 215 Impairs the p53/MDM2 Autoregulatory Loop in Multiple Myeloma Development
5. IKAROS expression in distinct bone marrow cell populations as a candidate biomarker for outcome with lenalidomide‐dexamethasone therapy in multiple myeloma
6. Assessment of Associations between Derived Response and Overall Survival in Patients with Multiple Myeloma Using a US-Based Electronic Health Records Database
7. Lab-Based Response Assessment Algorithm Recapitulates Investigator's Response Assessment in the Phase 3 Bellini Trial
8. Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma
9. Overexpression of HOXB7 and homeobox genes characterizes multiple myeloma patients lacking the major primary immunoglobulin heavy chain locus translocations
10. MiR-16 regulates crosstalk in NF-κB tolerogenic inflammatory signaling between myeloma cells and bone marrow macrophages
11. Cyclooxygenase-2 (COX-2) is frequently expressed in multiple myeloma and is an independent predictor of poor outcome
12. Effect of Recombinant Zoster Vaccine on Incidence of Herpes Zoster After Autologous Stem Cell Transplantation A Randomized Clinical Trial
13. Indoleamine 2,3-dioxygenase 1 (IDO1) activity correlates with immune system abnormalities in multiple myeloma
14. Evaluating Suspected Cardiac Amyloidosis
15. Report from the European Myeloma Network on interphase FISH in multiple myeloma and related disorders
16. TOURMALINE-MM1: new oral triplet combination for patients with relapsed/refractory multiple myeloma
17. Correction: In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation
18. High XBP1 expression is a marker of better outcome in multiple myeloma patients treated with bortezomib
19. Cancer-Selective Targeting of the NF-kappa B Survival Pathway with GADD45 beta/MKK7 Inhibitors
20. Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: a prospective analysis
21. RETRACTED: Downregulation of p53-inducible microRNAs 192, 194, and 215 Impairs the p53/MDM2 Autoregulatory Loop in Multiple Myeloma Development
22. Proteomic Characterization of Circulating Extracellular Vesicles Identifies Novel Serum Myeloma Associated Markers
23. Small RNA Deep Sequencing Highlights the Important Contribution of Mirnas in Regulating IRF4/c-Myc Axis in Myeloma Development
24. Lenalidomide for Multiple Myeloma
25. MET/HGF pathway in multiple myeloma: from diagnosis to targeted therapy?
26. European Myeloma Network: the 3rd Trialist Forum Consensus Statement from the European experts meeting on multiple myeloma
27. Proteomic Characterization of the Multiple Myeloma Bone Marrow Extracellular Matrix
28. In Multiple Myeloma, Minimal Residual Disease (MRD) Is an Early Predictor of Progression and Is Modulated By Maintenance Therapy with Lenalidomide
29. Cancer-Selective Targeting of the NF-κB Survival Pathway with GADD45β/MKK7 Inhibitors
30. RETRACTED: Downregulation of p53-inducible microRNAs 192, 194, and 215 Impairs the p53/MDM2 Autoregulatory Loop in Multiple Myeloma Development
31. Abstract 4855: Proteomic characterization of the extracellular matrix in multiple myeloma
32. The potential of miRNAs as biomarkers for multiple myeloma
33. Minimal Residual Disease Monitoring During Maintenance In Multiple Myeloma Patients
34. Long-Term Molecular Results Of The Gimema VEL-03-096 Trial: Molecular Remission Achievement and Loss Are Major Outcome Predictors
35. Circulating Mir-16 and Mir-25 As New Prognosticators For Multiple Myeloma
36. A Phase II Study With Carfilzomib, Cyclophosphamide and Dexamethasone (CCd) For Newly Diagnosed Multiple Myeloma
37. Report from the European Myeloma Network on interphase FISH in multiple myeloma and related disorders
38. In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation
39. Abstract 1122: In vivo NCL-targeting affects breast cancer aggressiveness through miRNA regulation.
40. High Rates of Prolonged Molecular Remissions After Tandem Autologous-Nonmyeloablative Allografting in Newly Diagnosed Myeloma
41. MiR-221 and MiR-222 Patterns Characterize Burkitt Lymphoma in Human and Mouse Model
42. miRNA in Serum and Bone Marrow Plasma Cells From Multiple Myeloma Patients.
43. Abstract 5032: New insights of miR-221 and miR-222 cluster functions in Burkitt lymphoma.
44. LONG-TERM RESULTS of the GIMEMA VTD Consolidation TRIAL In Autografted MULTIPLE Myeloma PATIENTS (VEL-03-096): IMPACT of Minimal RESIDUAL DISEASE Detection by REAL Time Quantitative PCR On LATE Recurrences and Overall SURVIVAL
45. Severe Telomeric Erosion In Ph-Negative Hematopoiesis After Successful CML Treatment: Association with Acquired Cytogenetic Lesions and Hematological Toxicity.
46. High Expression of mRNA and Gene Amplification of Met In Myeloma Plasma Cells Characterize a More Aggressive Disease
47. A Multicenter, Open Label Study of Oral Lenalidomide and Prednisone (RP) Followed by Oral Lenalidomide Melphalan and Prednisone (MPR) and Oral Lenalidomide Maintenance In Newly Diagnosed Elderly Multiple Myeloma Patients
48. IGH Repertoire Analysis In Multiple Myeloma (MM): Lack of Intra-Disease Homology and Occasional Clustering with Sequences of Other B-Cell Neoplasms Sharing Identical Geographical Origin
49. Are the Myeloma Bone Microevironment Cells Tumoral or Not?.
50. Ph-Negative Hematopoiesis Emerging After Successful Treatment of Chronic Myeloid Leukemia Displays Severe and Persistent Telomeric Loss Which Is Particularly Prominent in Patients with Acquired Cytogenetic Abnormalities.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.